RGT 274
Alternative Names: RGT-274Latest Information Update: 06 Mar 2024
At a glance
- Originator Regor Therapeutics
- Class
- Mechanism of Action Glucagon-like peptide-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 22 Dec 2023 Preclinical trials in Metabolic disorders in China (unspecified route) before December 2023 (Regor Therapeutics pipeline, December 2023)